Dr. Lichtenstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11301 Wilshire Blvd
Los Angeles, CA 90073Phone+1 310-478-3711Fax+1 310-268-4508
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 1977 - 1978- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1975 - 1977
UPMC Medical EducationResidency, Internal Medicine, 1972 - 1975
George Washington University School of Medicine and Health SciencesClass of 1972
Certifications & Licensure
CA State Medical License 1975 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- 1063 citationsHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.Elizabeta Nemeth, Erika V. Valore, Mary C. Territo, Gary J. Schiller, Alan Lichtenstein
Blood. 2003-04-01 - 110 citationsMechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity.Alan Lichtenstein, Tomas Ganz, The-Minh Nguyen, Michael E. Selsted, Robert I. Lehrer
Journal of Immunology. 1988-04-15 - 49 citationsIL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.Yijiang Shi, Patrick Frost, Bao Q. Hoang, Angelica Benavides, Sanjai Sharma
Cancer Research. 2008-12-15
Grant Support
- Regulation Of C-MYC Translation By Hnrnp A1: Role In Multiple Myeloma Tumor RespoNational Cancer Institute2009–2011
- Use Of CCI-779 In Multiple MyelomaNational Cancer Institute2008–2009
- Sensitivity Multiple Myeloma Cells To Mtor InhibitorsNational Cancer Institute2005–2009
- EBV Lytic Re-Activation In Nasopharyngeal CarcinomaNational Cancer Institute2005–2006
- The Akt-Mtor Pathway In Multiple MyelomaNational Cancer Institute2002–2005
- Anti-Tumor Properties Of Acute InflammationNational Cancer Institute1985–1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
